[go: up one dir, main page]

ES2662847T3 - Formulaciones novedosas de inhalación - Google Patents

Formulaciones novedosas de inhalación Download PDF

Info

Publication number
ES2662847T3
ES2662847T3 ES14174889.7T ES14174889T ES2662847T3 ES 2662847 T3 ES2662847 T3 ES 2662847T3 ES 14174889 T ES14174889 T ES 14174889T ES 2662847 T3 ES2662847 T3 ES 2662847T3
Authority
ES
Spain
Prior art keywords
lactose monohydrate
monohydrate particles
inhalation formulations
volume
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14174889.7T
Other languages
English (en)
Inventor
Ali TÜRKYILMAZ
Devrim Celik
Onur Mutlu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arven Ilac Sanayi ve Ticaret AS
Original Assignee
Arven Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi ve Ticaret AS filed Critical Arven Ilac Sanayi ve Ticaret AS
Application granted granted Critical
Publication of ES2662847T3 publication Critical patent/ES2662847T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación en polvo seco que comprende a. un dihidrato de fumarato de 5 formoterol micronizado y budesonida micronizada y, b. monohidrato de lactosa como un portador que comprende partículas de monohidrato de lactosa finas y partículas de monohidrato de lactosa gruesas; el tamaño de partícula d0.5 por volumen de las partículas de monohidrato de lactosa finas está entre 0.5 μm y 25 μm y el tamaño de partícula d0.5 por volumen de las partículas de monohidrato de lactosa gruesas está entre 40 μm y 200 μm, caracterizado porque la densidad a granel vertida de la formulación en polvo seco está entre 0.42 g/ml y 0.57 g/ml.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES14174889.7T 2013-07-01 2014-06-30 Formulaciones novedosas de inhalación Active ES2662847T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201307891 2013-07-01
TR201307891 2013-07-01

Publications (1)

Publication Number Publication Date
ES2662847T3 true ES2662847T3 (es) 2018-04-10

Family

ID=49674361

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14174889.7T Active ES2662847T3 (es) 2013-07-01 2014-06-30 Formulaciones novedosas de inhalación

Country Status (5)

Country Link
EP (2) EP2821061B1 (es)
ES (1) ES2662847T3 (es)
PL (1) PL2821061T3 (es)
PT (1) PT2821061T (es)
TR (1) TR201802969T4 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107929257B (zh) * 2017-12-01 2019-04-16 广东一力集团制药股份有限公司 一种酒石酸阿福特罗粉吸入剂胶囊及其制备方法
WO2020240350A1 (en) * 2019-05-24 2020-12-03 Glenmark Pharmaceutical Limited An inhalable fixed dose powder composition comprising glycopyrronium, formoterol and fluticasone propionate
EP4108230A1 (en) * 2021-06-24 2022-12-28 Laboratoires SMB New dry powder composition of tiotropium for inhalation
US20250205153A1 (en) 2022-03-31 2025-06-26 Hovione Scientia Limited Inhalation composite and carrier based formulation combination

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.

Also Published As

Publication number Publication date
TR201802969T4 (tr) 2018-03-21
PL2821061T3 (pl) 2018-05-30
EP2821062A1 (en) 2015-01-07
EP2821061A1 (en) 2015-01-07
PT2821061T (pt) 2018-03-13
EP2821061B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
ES2662847T3 (es) Formulaciones novedosas de inhalación
AR098640A1 (es) Inhalador de polvo seco
CL2016002714A1 (es) Un inhalador articulado de cápsula
CL2015002787A1 (es) Formulación de acetato de abiraterona.
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
GEP20186853B (en) Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
CL2016001547A1 (es) Composiciones para el cuidado oral
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
GT201400182A (es) Formulaciones farmacéuticas novedosas
PE20141703A1 (es) Formulacion seca en polvo que comprende un corticoesteroide y un beta-adrenergico para administrar por inhalacion
PE20171022A1 (es) Inhalador de polvo seco y mecanismo para su accionamiento por inhalacion
MX2016006916A (es) Composicion farmaceutica, que comprende particulas de aglutinante de fosfato.
EA201590734A1 (ru) Вдыхаемые лекарственные средства
AR091161A1 (es) Composicion farmaceutica para inhalacion, metodo, uso
SG11201507667SA (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
ES2525833T3 (es) Supresión del crecimiento del cáncer y la metástasis mediante el uso de derivados de ácido nordihidroguayarético con 7-hidroxiestaurosporina
MX2017008307A (es) Articulos abrasivos y metodos para formarlos.
MY178819A (en) Methods and systems for conditioning of particulate crystalline materials
MX2015014338A (es) Composicion farmaceutica que continen budesonida y formoterol.
MX2016007266A (es) Metodo para preparar composiciones secas para inhalacion en polvo.
MX365591B (es) Formulacion de metaxalona.
ES2565637T3 (es) Método de obtención de nanocristales de fluorapatita facetados
ES2664737T3 (es) Tratamiento de enfermedades intestinales inflamatorias con clinoptilolita